Reinforcing the social compromise of accelerated approval
- 3 July 2018
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 15 (10) , 596-597
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016JAMA Oncology, 2018
- A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and BiologicsJAMA Oncology, 2018
- Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug AdministrationJAMA, 2017
- Accelerated Approval and Expensive Drugs — A Challenging CombinationNew England Journal of Medicine, 2017
- Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015Annals of Oncology, 2017
- Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort studyBMJ, 2015